{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:03:55Z","timestamp":1791461035143,"version":"4.3.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Med. Toxicol."],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1007\/bf03160978","type":"journal-article","created":{"date-parts":[[2009,8,27]],"date-time":"2009-08-27T07:07:46Z","timestamp":1251356866000},"page":"27-31","source":"Crossref","is-referenced-by-count":22,"title":["Neuroleptic malignant syndrome developing after acute overdose with olanzapine and chlorpromazine"],"prefix":"10.1007","volume":"5","author":[{"given":"Enasio","family":"Morris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Digby","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andis","family":"Graudins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"issue":"1","key":"BF03160978_CR1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/00004714-200302000-00016","volume":"23","author":"JS Goveas","year":"2003","unstructured":"Goveas JS, Hermida A. Olanzapine induced typical neuroleptic malignant syndrome.J Clin Psychopharmacol 2003; 23(1):101\u2013102.","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"BF03160978_CR2","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1600-0447.2005.00578.x","volume":"112","author":"J Nielsen","year":"2005","unstructured":"Nielsen J, Bruhn AM. Atypical neuroleptic malignant syndrome caused by olanzapine.Acta Psychiatr Scand 2005;112(2): 238\u2013240.","journal-title":"Acta Psychiatr Scand"},{"issue":"3","key":"BF03160978_CR3","first-page":"49","volume":"35","author":"KL Hall","year":"2001","unstructured":"Hall KL, Taylor WH, Ware MR. Neuroleptic malignant syndrome due to olanzapine.Psychopharmacol Bull 2001; 35(3):49\u201354.","journal-title":"Psychopharmacol Bull"},{"issue":"5","key":"BF03160978_CR4","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S0278-5846(02)00202-6","volume":"26","author":"VP Kontaxakis","year":"2002","unstructured":"Kontaxakis VP, Havaki-Kontaxaki BJ, Christodoulou NG, et al. Olanzapine-associated neuroleptic malignant syndrome.Prog Neuropsychopharmacol Biol Psychiatry 2002; 26(5):897\u2013902.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"6","key":"BF03160978_CR5","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/00004714-200012000-00021","volume":"20","author":"D Sierra-Biddle","year":"2000","unstructured":"Sierra-Biddle D, Herran A, Diez-Aja S, et al. Neuroleptic malignant syndrome and olanzapine.J Clin Psychopharmacol 2000;20(6): 704\u2013705.","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"BF03160978_CR6","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/YIC.0b013e32805aedf5","volume":"22","author":"M Morgan","year":"2007","unstructured":"Morgan M, Hackett LP, Isbister GK. Olanzapine overdose: A series of analytically confirmed cases.Int Clin Psychopharmacol 2007;22(3):183\u2013186.","journal-title":"Int Clin Psychopharmacol"},{"issue":"2","key":"BF03160978_CR7","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0196-0644(99)70243-X","volume":"34","author":"LG Cohen","year":"1999","unstructured":"Cohen LG, Fatalo A, Thompson BT, et al. Olanzapine overdose with serum concentrations.Ann Emerg Med 1999; 34(2):275\u2013278.","journal-title":"Ann Emerg Med"},{"issue":"1","key":"BF03160978_CR8","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/00004714-200302000-00016","volume":"23","author":"JS Goveas","year":"2003","unstructured":"Goveas JS, Hermida A. Olanzapine induced \u201ctypical\u201d neuroleptic malignant syndrome.J Clin Psychopharmacol 2003; 23(1):101\u2013102.","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"BF03160978_CR9","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1600-0447.2005.00578.x","volume":"112","author":"J Nielsen","year":"2005","unstructured":"Nielsen J, Bruhn AM. Atypical neuroleptic malignant syndrome caused by olanzapine.Acta Psychiatr Scand 2005;112(3): 238\u2013240; discussion 40.","journal-title":"Acta Psychiatr Scand"},{"issue":"6","key":"BF03160978_CR10","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1176\/appi.psy.42.6.528","volume":"42","author":"RA Philibert","year":"2001","unstructured":"Philibert RA, Adam LA, Frank FM, et al. Olanzapine usage associated with neuroleptic malignant syndrome.Psychosomatics 2001;42(6):528\u2013529.","journal-title":"Psychosomatics"},{"key":"BF03160978_CR11","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1176\/ajp.145.4.517","volume":"145","author":"AJ Gelenberg","year":"1988","unstructured":"Gelenberg AJ, Bellinghausen B, Wojcik JD, et al. A prospective survey of neuroleptic malignant syndrome in a short term psychiatry hospital.Am J Psychiatry 1988;145: 517\u2013518.","journal-title":"Am J Psychiatry"},{"issue":"8","key":"BF03160978_CR12","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1176\/ajp.155.8.1113","volume":"155","author":"S Hansan","year":"1998","unstructured":"Hansan S, Buckley P. Novel antipsychotics and the neuroleptic malignant syndrome.Am J Psychiatry 1998;155(8): 1113\u20131116.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"BF03160978_CR13","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1475-2832-2-10","volume":"2","author":"VP Kontaxakis","year":"2003","unstructured":"Kontaxakis VP, Havaki-Kontaxaki BJ, Christodoulou NG, et al. Olanzapine-associated neuroleptic malignant syndrome: Is there an overlap with the serotonin syndrome?Ann Gen Hosp Psychiatry 2003;2(1):10.","journal-title":"Ann Gen Hosp Psychiatry"},{"key":"BF03160978_CR14","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1176\/ajp.143.10.1227","volume":"143","author":"HGJ Pope","year":"1986","unstructured":"Pope HGJ, Keck PEJ, McElroy SL. Frequency and presentation of neuroleptic malignant syndrome in large psychiatric hospital.Am J Psychiatry 1986;143:1227\u20131233.","journal-title":"Am J Psychiatry"},{"key":"BF03160978_CR15","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1176\/ajp.154.8.1156","volume":"154","author":"P Sachdev","year":"1997","unstructured":"Sachdev P, Mason C, Hadzi-Pavlovic D. Case control study of neuroleptic malignant syndrome.Am J Psychiatry 1997; 154:1156\u20131158.","journal-title":"Am J Psychiatry"},{"key":"BF03160978_CR16","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/qjmed\/hcg109","volume":"96","author":"EJ Dunkley","year":"2003","unstructured":"Dunkley EJ, Isbister GK, Sibbritt D, et al. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity.QJM 2003;96: 635\u2013642.","journal-title":"QJM"},{"key":"BF03160978_CR17","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1176\/ajp.144.10.1344","volume":"144","author":"PE Keck","year":"1987","unstructured":"Keck PE Jr, Pope HG Jr, McElroy SL. Frequency and presentation of neuroleptic malignant syndrome: a prospective study.Am J Psychiatry 1987;144:1344\u20131346.","journal-title":"Am J Psychiatry"},{"key":"BF03160978_CR18","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0736-4679(00)00263-8","volume":"19","author":"SC Stanfield","year":"2000","unstructured":"Stanfield SC, Privette T. Neuroleptic malignant syndrome associated with olanzapine therapy: a case report.J Emerg Med 2000;19:355\u2013357.","journal-title":"J Emerg Med"},{"issue":"3","key":"BF03160978_CR19","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0033-3182(99)71247-8","volume":"40","author":"JE Apple","year":"1999","unstructured":"Apple JE, Van Hauer G. Neuroleptic malignant syndrome associated with olanzapine therapy.Psychosomatics 1999;40(3): 267\u2013277.","journal-title":"Psychosomatics"},{"issue":"2","key":"BF03160978_CR20","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/01.yct.0000159325.08303.45","volume":"21","author":"F Ozer","year":"2005","unstructured":"Ozer F, Meral H, Ayadin B, et al. Electroconvulsive therapy in drug-induced psychiatric states and neuroleptic malignant syndrome.J ECT 2005;21(2):125\u2013127.","journal-title":"J ECT"},{"issue":"4","key":"BF03160978_CR21","first-page":"267","volume":"8","author":"WA Scheftner","year":"1992","unstructured":"Scheftner WA, Shulman RB. Treatment choice in neuroleptic malignant syndrome.Convuls Ther 1992;8(4): 267\u2013279.","journal-title":"Convuls Ther"},{"key":"BF03160978_CR22","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/0006-3223(86)90249-0","volume":"21","author":"S Rotheke","year":"1986","unstructured":"Rotheke S, Bush D. Neuropsychological sequelae of Neuroleptic Malignant Syndrome.Biol Psychiatry 1986;21: 838\u2013841.","journal-title":"Biol Psychiatry"}],"container-title":["Journal of Medical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03160978.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03160978\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03160978","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T22:36:26Z","timestamp":1558478186000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03160978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["BF03160978"],"URL":"https:\/\/doi.org\/10.1007\/bf03160978","relation":{},"ISSN":["1556-9039","1937-6995"],"issn-type":[{"value":"1556-9039","type":"print"},{"value":"1937-6995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3]]}}}